Recently, one study not only confirmed the high expression of NKG2DL in human glioma cell lines, cancer stem cells, and tumor samples, but also suggested that CAR-T cells expressing NKG2D are an encouraging therapeutic approach for glioma patients [49]. The gene discussed is KLRK1; the disease is glioma.